Premium
Immunotherapy with effector cells and IL‐2 of lymph node metastases of human squamous‐cell carcinoma of the head and neck established in nude mice
Author(s) -
Chikamatsu Kazuaki,
Reichert Torsten E.,
Kashii Yoshiro,
Saito Takao,
Kawashiri Shuichi,
Yamamoto Etsuhide,
Whiteside Theresa L.
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990812)82:4<532::aid-ijc11>3.0.co;2-g
Subject(s) - lymph node , adoptive cell transfer , cytotoxic t cell , medicine , cancer research , immunotherapy , head and neck squamous cell carcinoma , nude mouse , effector , metastasis , lymphokine activated killer cell , ctl* , immunology , immune system , cancer , pathology , t cell , biology , cd8 , in vitro , head and neck cancer , interleukin 21 , biochemistry
We have previously reported that immune anti‐tumor effector cells, both cytotoxic T lymphocytes (CTLs) and IL‐2‐activated natural killer (A‐NK) cells, are effective at eliminating human head‐and‐neck cancer (HNC) targets in vitro and in vivo in xenograft models. In this study, these 2 types of human effector cell were compared for the ability to prevent the development of lymph node metastases in a metastasis model of human squamous‐cell carcinoma of the head and neck (SCCHN) established in nude mice. A tumor cell line, OSC‐19, was injected into the floor of the mouth in nude mice, and the tumor grew progressively and metastasized to cervical lymph nodes by day 21. As effector cells, a human HLA‐A2‐restricted CTL line recognizing a shared antigen on OSC‐19 and human non‐MHC‐restricted A‐NK cells were used. Both types of effector cell mediated high levels of lysis against OSC‐19 targets in 4‐hr 51 Cr‐release assays. Administration of human CTLs or A‐NK cells and IL‐2 to the site of tumor growth in mice with 7‐day OSC‐19 tumors resulted in significant reduction of the number of lymph node metastases relative to untreated or sham‐operated controls or to mice treated with IL‐2 without the effector cells. Our results suggest that in a xenograft model of human SCCHN implanted in the oral cavity of nude mice, the development of lymph node metastases can be successfully controlled by adoptive transfer of human SCCHN‐specific CTLs or SCCHN‐reactive A‐NK cells plus IL‐2. Int. J. Cancer 82:532–537, 1999. © 1999 Wiley‐Liss, Inc.